ReviewInternational journal of women's health2015
Critical appraisal of paroxetine for the treatment of vasomotor symptoms.
Review in International journal of women's health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02749747 (Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric), which is not on this map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric: a Double-blind Randomized Clinical Trial
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Magnitude of placebo response in clinical trials of paroxetine for vasomotor symptoms: a meta-analysis.Frontiers in psychiatry · 2023Pooled it
- The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials.Iranian journal of medical sciences · 2022Pooled it
- Guideline
- Efficacy of Treatments in Reducing Facial Erythema in Rosacea: A Systematic Review.Journal of cutaneous medicine and surgeryPooled it
- Utilization of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms of menopause in a real-world setting.Menopause (New York, N.Y.) · 2026Article
- Review
- Role of the pharmacist in the management of postmenopausal breast cancer treatment with vasomotor symptoms: A case report.Exploratory research in clinical and social pharmacy · 2023Article
- [Preventive activities in women. PAPPS update 2022].Atencion primaria · 2022Article
- Hormone Therapy and Risk of Breast Cancer: Where Are We Now?Journal of menopausal medicine · 2022Review
- A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms.International journal of women's health · 2022Review
- [Preventive activities in women's care].Atencion primaria · 2020Article
- Comparison of the effects of stellate ganglion block and paroxetine on hot flashes and sleep disturbance in breast cancer survivors.Cancer management and research · 2018Article
- Comparative Efficacy and Safety of Clonazepam versus Nortrptilline on Menopausal Symptom among Forty Plus Women: A Prospective, Open-Label Randomized Study.Journal of mid-life healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVasomotor symptoms (VMS), characterized by hot flashes and night sweats, are the most commonly reported symptoms associated with estrogen deficiency during menopause and occur in up to 70% of women. The goal of treatment is to reduce the frequency and severity of symptoms. Although hormone therapy (HT) is generally recommended as first-line treatment, it is not appropriate for all patients. Antidepressants, specifically selective serotonin reuptake inhibitors, have been evaluated and utilized internationally for alternative treatment for VMS. In 2013, paroxetine mesylate (Brisdelle(®)) received a US Food and Drug Administration-labeled indication for moderate-to-severe hot flashes, making it the first nonhormonal treatment for VMS associated with menopause. The objective of this review is to critically evaluate available clinical data regarding the efficacy and safety of paroxetine for the treatment of VMS in menopausal women.
methodsMEDLINE, PubMed, and Google Scholar were searched using the keywords paroxetine, vasomotor symptoms, hot flashes, and menopause. Searches were limited to humans, English language, and clinical trial design with a primary outcome of hot flash/vasomotor changes.
resultsParoxetine (hydrochloride and mesylate) has been associated with a 33%-67% reduction in hot flash frequency with 6-12 weeks of treatment compared to 13.7%-37.8% reductions with placebo in patients both with and without a history of breast cancer. It was also associated with significant reductions in hot flash severity. Benefits of treatment persisted through 24 weeks in the study of the longest duration. Most adverse effects reported were of mild-to-moderate severity, with improved tolerability associated with lower doses (7.5-12.5 mg/day).
conclusionParoxetine is a safe and effective therapy for the treatment of VMS during menopause. Paroxetine (7.5-12.5 mg/day) should be considered a first-line therapy option for VMS in patients when HT is either inappropriate or intolerable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.